Tanaka, Jon
January 2016
Berkeley Technology Law Journal;2016 Special Issue, Vol. 31, p659
Academic Journal
The article focuses on the decision of the U.S. Court of Appeals for the Federal Circuit in the case Amgen Inc. v. Sandoz Inc. on patent dance described in the Biologics Price Competition and Innovation Act (BPCIA) for biosimilar drug approval was not mandatory. It mentions that the U.S. Congress intended the patent dance to be mandatory to maintain an efficient and effective patent dispute resolution process for biosimilar and original biologic drug makers.


Related Articles

  • Johnson & Johnson Amgen's EPO Dispute Is Resolved.  // Chemical Market Reporter;10/28/2002, Vol. 262 Issue 15, p14 

    Reports on the resolution of the dispute over the rights to sell erythropoietin in the U.S. market between Johnson & Johnson and Amgen Inc. Amount of damages received by Amgen; Removal of an uncertainty of overhanging stock of J&J; Denial of the request of Amgen to terminate the 1985 license...

  • Back to the Future: Civil RICO in Off-Label Promotion Litigation. Cooney Jr., J. Gordon; Lavelle Jr., John P.; Shariati, Bahar // Defense Counsel Journal;Apr2010, Vol. 77 Issue 2, p168 

    The article discusses several court cases and analyzes the legal principles which have limited attempted expansion of civil Racketeer Influenced and Corrupt Organizations Act (RICO) in the U.S. It states that in the In re Epogen & Aranesp Off-Label Marketing, the plaintiffs allege that Amgen...

  • Keeping Current: Supreme Court Holds Proof of Materiality Not Required to Certify a Securities Fraud Class Action. Schwinger, Robert A.; Kruglak, Seth M. // Business Law Today;Mar2013, Vol. 22 Issue 3, p1 

    The article focuses on the Amgen Inc. v. Connecticut Retirement Plans and Trust Funds court case in the U.S. regarding the securities fraud class action. The plaintiffs in Amgen, various retirement plans and funds and individuals, filed securities fraud claims in federal court against Amgen for...

  • 15 states sue Amgen. Mullard, Asher // Nature Biotechnology;Jan2010, Vol. 28 Issue 1, p6 

    The article reports on the filing of a lawsuit by New York and 14 other U.S. states against Amgen alleging that the company illegally offered money to doctors to increase sales of its anemia drug, Aranesp, an erythropoietin-stimulating agent. According to a former employee of Amgen, the...

  • Biogen sues Amgen claiming patent violation.  // Medical Marketing & Media;Sep97, Vol. 32 Issue 9, p19 

    Reports on a lawsuit filed by Biogen Inc. against Amgen Inc. over alleged violations of three patents in connection with the manufacture of Infergen, Amgen's new drug for hepatitis C. Competition of the drug with Biogen's alpha interferon product, Intron A.

  • Steering Clear of the Courtroom: Alternative Dispute Resolution Gaining Ground. Rubenstein, David // Corporate Legal Times;Jan2002, Vol. 12 Issue 122, pCLT14 

    Reports on the emergence of alternative legal dispute resolution methods in South and Central America. Arbitration options; Effects of arbitration on relations between foreign business entities and host countries; Advantages of arbitration over litigation.

  • International Notes.  // Dispute Resolution Journal;Nov2009-Jan2010, Vol. 64 Issue 4, p13 

    The article discusses court cases involving dispute resolution.

  • Litigation nation.  // Lawyer (Online Edition);10/ 3/2013, p4 

    The article offers information on the reports and coverage related to litigations, dispute resolution and medical bills presented at the online version of the journal.

  • Litigation nation.  // Fundweb;10/ 3/2013, p17 

    The article focuses on the coverage and reports focused on litigations, health bills and dispute resolution presented in the online version of the journal.

  • Better than court. Markus, Stuart // Long Island Business News (7/1993 to 5/2009);02/02/2001, Vol. 48 Issue 5, p1A 

    Reports the growing trend in alternate dispute resolution (ADR)-style of settlement in commercial and personal cases in Long Island, New York. Connotations of lawsuit; Difference between arbitration and mediation; Implication for companies incorporating language into employment and business...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics